An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD) (NCT06254482)

🧪 Interventions in This Study

• Votoplam (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (24 Sites)

• Novartis Investigative Site — Clayton,
• Novartis Investigative Site — Westmead,
• Novartis Investigative Site — Innsbruck,
• Novartis Investigative Site — Ottawa,
• Novartis Investigative Site — Angers,
• Novartis Investigative Site — Marseille,
• Novartis Investigative Site — Paris,
• Novartis Investigative Site — Berlin,
• Novartis Investigative Site — Bochum,
• Novartis Investigative Site — Münster,
• Novartis Investigative Site — Ulm,
• Novartis Investigative Site — Bologna,
• Novartis Investigative Site — Milan,
• Novartis Investigative Site — San Giovanni Rotondo,
• Novartis Investigative Site — Leiden,
• Novartis Investigative Site — Christchurch,
• Novartis Investigative Site — Barakaldo,
• Novartis Investigative Site — Barcelona,
• Novartis Investigative Site — Burgos,
• Novartis Investigative Site — Madrid,
• Novartis Investigative Site — Birmingham,
• Novartis Investigative Site — Cardiff,
• Novartis Investigative Site — London,
• Novartis Investigative Site — Manchester,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Huntington Disease

• Neurobiological Predictors of Huntington's Disease (PREDICT-HD) — Iowa City, Iowa
• Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease — Nashville, Tennessee
• GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease — Birmingham, Alabama
• Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3) — Charlottesville, Virginia
• Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease — Rochester, New York

Explore by condition: All Huntington Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.